Pancreatic Cancer Research

ResearcherLoyola University Medical CenterActive in the last 2 years

Ali Vaziri Gohar

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6924-8691; OpenAlex author ID A5052538753. Sources: OpenAlex.

Their work

Papers
13 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
36
Papers, trials and grants by year

2017: 1 paper · 2018: 2 papers · 2019: none · 2020: none · 2021: 1 paper · 2022: 4 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 13

  1. A ketogenic diet sensitizes pancreatic cancer to glutamine metabolism inhibitors. Co-author DOI 10.1016/j.xcrm.2026.102770↗
  2. Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies. Co-author DOI 10.1158/2767-9764.crc-25-0338↗
  3. Cytosolic transport of citrate protects nutrient-austere pancreatic cancer from ferroptosis Last author DOI 10.1101/2025.01.15.633097↗
  4. IDH1 Inhibition Potentiates Chemotherapy Efficacy in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-23-1895↗
  5. Increased glucose availability sensitizes pancreatic cancer to chemotherapy. Co-author DOI 10.1038/s41467-023-38921-8↗
  6. Prodromal depression and anxiety are associated with worse treatment compliance and survival among patients with pancreatic cancer. Co-author DOI 10.1002/pon.5945↗
  7. Surgical techniques and tips for a reliable murine model of primary and metastatic pancreatic cancer Co-author DOI 10.1101/2022.07.30.502136↗
  8. IDO1 Is a Therapeutic Target for Pancreatic Cancer-Associated Depression. Co-author DOI 10.1158/1535-7163.mct-22-0055↗
  9. Liver Endothelium Microenvironment Promotes HER3-mediated Cell Growth in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.26502/jcsct.5079182↗
  10. Nuclear Receptor 4A2 (NR4A2/NURR1) Regulates Autophagy and Chemoresistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2767-9764.crc-21-0073↗
  11. Metabolic Dependencies in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2018.00617↗
  12. Corrigendum: Metabolic Dependencies in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2018.00672↗
  13. Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells. Co-author DOI 10.1158/0008-5472.can-17-0015↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jordan Michael Winter · 11 shared papers, 2017–2026 · strength 1.62
  2. Mehrdad Zarei · 9 shared papers, 2021–2026 · strength 1.46
  3. Omid Hajihassani · 8 shared papers, 2022–2026 · strength 1.33
  4. Jonathan J. Hue · 7 shared papers, 2022–2026 · strength 1.19
  5. Jonathan Robert Brody · 7 shared papers, 2017–2026 · strength 0.97
  6. Erryk Katayama · 4 shared papers, 2022–2026 · strength 0.69
  7. Mahsa Zarei · 5 shared papers, 2017–2023 · strength 0.54
  8. Luke Daniel Rothermel · 3 shared papers, 2022–2026 · strength 0.51
  9. Moeez Ghani Rathore · 3 shared papers, 2022–2026 · strength 0.47
  10. Rui Wang · 2 shared papers, 2022–2023 · strength 0.27
  11. Lisa M. Coussens · 1 shared paper, 2026 · strength 0.23
  12. Katie E. Blise · 1 shared paper, 2026 · strength 0.23
  13. Sami O. Abul-Khoudoud · 1 shared paper, 2026 · strength 0.23
  14. Robert L Eil · 1 shared paper, 2026 · strength 0.23
  15. Rosalie C. Sears · 1 shared paper, 2026 · strength 0.23
  16. Charles D. Lopez · 1 shared paper, 2026 · strength 0.23
  17. Adam Kneebone · 1 shared paper, 2025 · strength 0.23
  18. William C. Small · 1 shared paper, 2025 · strength 0.23
  19. Joshua D. Rabinowitz · 1 shared paper, 2026 · strength 0.19
  20. Faith Nakazzi · 1 shared paper, 2024 · strength 0.18
  21. Akram S. Shalaby · 1 shared paper, 2024 · strength 0.18
  22. Wei Zhang · 1 shared paper, 2022 · strength 0.15
  23. Mohamedraed Elshami · 1 shared paper, 2022 · strength 0.13
  24. Nathaniel E Davis · 1 shared paper, 2022 · strength 0.13
  25. Li Zhang · 1 shared paper, 2023 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.